TNGX

Tango Therapeutics, Inc.

11.42 USD
-0.02 (-0.17%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Tango Therapeutics, Inc. stock is down -11.34% since 30 days ago. The next earnings date is Mar 25, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 25% of the previous 3 March’s closed higher than February. 100% of analysts rate it a buy.

About Tango Therapeutics, Inc.

Tango Therapeutics, Inc. discovers and develops drugs for the treatment of cancer. Lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. Company also develops Ubiquitin-specific protease 1 and Target 3 for STK11-mutant cancers.